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Abstract Amorphization is nowadays a method that is
frequently applied in the pharmaceutical industry. The
primary aim of this study is to achieve the amorphization of
clopidogrel hydrogen sulphate as an active pharmaceutical
ingredient (API) with various solvents and to choose the
most suitable one. A secondary aim was to determine the
glass-transition temperature (Tg) of this API and to classify
it as a good or poor glass former. To investigate the
amorphous form, differential scanning calorimetry, X-ray
powder diffraction, and FT-IR analysis were applied. The
melting point (Tm) was 177.4 C (450.6 K), and Tg was
determined to be 88.9 C (362.1 K). The quotient Tg/Tm
was 0.80, and this API was therefore classified as a good
glass former.
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Introduction
The two forms of solids are the amorphous and the crys-
talline forms [1]. The amorphous form is widely applied in
industrial fields such as the plastics industry, the textile
industry, the food industry, the production of semicon-
ductors, ceramics and optical glasses, and naturally the
pharmaceutical industry. The importance of amorphization
is currently increasing in consequence of its value in the
pharmaceutical industry for various reasons [2]:
– The development of many poorly water-soluble active
pharmaceutical ingredients (APIs) [3].
– The polymorphism of APIs, the different forms having
different physical and/or chemical properties [4], which
can be interconverted and thus display changing
solubility, compressibility, and not at least physiolog-
ical effects.
– The processing of crystalline drug substances lead run
into difficulties, whereas the amorphous form can often
be treated easily. In many cases, for example, the
compressibility of the amorphous form is better than
that of the crystalline form [1].
– Economic aspects are also involved when the aim of
amorphization is a new patent relating to the amor-
phous form.
Amorphous forms of APIs have many useful properties.
Some of the most important ones: higher water solubility
and higher dissolution rate relative to the crystalline forms
[5–8], as there is no lattice energy, which is a thermody-
namic barrier to dissolution [9]. There are two feasible
ways to amorphize crystalline APIs:
– An amorphous API can be produced alone, without
additives, but it must be mentioned that amorphous
solids generally have lower stability than the corre-
sponding crystals because of the higher energy level
[10–12].
– Otherwise, pharmaceutical technologists often have to
apply crystallization inhibitors as additives [13–15].
These inhibitors are usually hydrophilic carriers, which
can increase the wetting property of APIs too. This
mostly results in more stable product.
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Both routes for the amorphization of crystalline APIs
can be applied with the solvent method, hot-melt technol-
ogy and milling technology [16].
The solvent method is one of the simplest processes for
amorphization in industry. It is important that the agent
must dissolve without leaving a residue. If crystals remain
in the system, then these could start nucleation by acting as
seeding crystals in the phase of supersaturation during the
evaporation of the solvent.
In pharmaceutical systems, amorphous materials are of
great importance both as auxiliary agents and as APIs.
Crystalline systems can be characterized by their melt-
ing points (Tm), but amorphous materials do not possess
this characteristic temperature parameter. They can rather
be defined by the glass-transition temperature (Tg), below
which amorphous materials are brittle and above which
they are in a liquid or rubbery state. The Tg lies in the
interval from approximately 2/3 to 4/5 of the Tm (in
Kelvin) [2]. For investigations of the amorphous form and
Tg, the differential scanning calorimetry (DSC) is a suitable
experimental method [17, 18].
Crystalline agents can be divided into poor (or fragile)
glass formers and good (or strong) glass formers. In the
case of poor or fragile glass formers Tg/Tm \ 0.7, and in
the case of good or strong glass formers Tg/Tm [ 0.7
[19]. (In an another publications the limit is given as 1.5,
but in this case the quotient is Tm/Tg, when Tm/Tg [ 1.5
the material is good glass former [11, 20].) Good glass
formers exhibit minimal molecular mobility changes at
Tg, and hence the shift in heat capacity tends to be
small.
In this study, the crystalline API which was subjected to
amorphization was clopidogrel hydrogen sulfate (clopido-
grel bisulfate) (CLP), a potent oral antiplatelet agent often
used in the treatment of coronary artery disease, peripheral
vascular disease, and cerebrovascular disease as Plavix or
Iscover [21]. The chemical formula is C16H16ClNO2S
H2SO4 and the molecular mass is 419.9. Chemically it is
classed among the thiophenes, and its systematic IUPAC
name is methyl (?)-(S)-alpha-(2-chlorophenyl)-6,7-dihy-
drothieno[3,2-c]pyridine-5(4H)-acetate sulfate. Six differ-
ent polymorphic forms and an amorphous form of the drug
have been identified, but only forms I and II are used in
pharmaceutical formulations [22, 23]. The polymorphic
and amorphous forms of this drug are dealt within a
number of patents and articles [24–26].
The primary aim of this study is to achieve the amor-
phization of CLP by the solvent method and to select the
most suitable solvent. A further aim is to characterize the
amorphous form via thermoanalytical parameters and to
classify it as a poor or a good glass former. We additionally




CLP polymorphic form II (EGIS, Budapest, Hungary) was
used as the crystalline API. Ethanol (Merck, Budapest,
Hungary), methanol (Merck, Budapest, Hungary), and
acetone (Reanal, Budapest, Hungary) were used as
solvents.
Methods
Preparation of amorphous form
Amorphous samples were made using ethanol and metha-
nol. 1.00-g CLP was dissolved in 10.00-g ethanol or 4.00-g
methanol with magnetic stirrer (Velp Scientifica, Europe)
for 5 min at room temperature. The solvent was evaporated
by two methods: with blown room temperature air or by
vacuum (Binder, Germany). 1.00-g CLP was treated with
20.00-g acetone with magnetic mixing for 15 min at room
temperature and the solvent was then evaporated in vac-
uum (Binder, Germany). After drying, samples were pul-
verized in a porcelain mortar with a pestle.
Differential scanning calorimetry
DSC studies were performed with a DSC 821e instrument
(Mettler-Toledo, Switzerland) with samples of approxi-
mately 4.8–5.2 mg weighed into non-hermetically sealed
aluminum pans. The samples were heated from 25 to
200 C at heating rate of 5 C min-1. The instrument was
calibrated with the use of indium.
FT-IR analysis
The FT-IR apparatus was an Avatar 330 FT-IR spectrom-
eter (Thermo Nicolet, USA). The sample, with a CLP
content of 0.5 mg, was ground and mixed with 150 mg of
dry KBr in an agate mortar, and the mixture was then
compressed into a disk at 98.1 kN (cm2)-1. Each disk was
scanned 64 times at a resolution of 2 cm-1 over the
wavenumber region 4000–400 cm-1.
X-ray powder diffraction (XRPD)
XRPD was performed with an X-ray Diffractometer
Miniflex II (Rigaku, Tokyo, Japan), where the tube anode
was Cu with Ka = 1.5405 A˚. The pattern was collected at
a tube voltage of 30 kV and a tube current of 15 mA in step
scan mode (4 min-1). The instrument was calibrated with
Si.




Prepared samples were measured primarily by DSC. With
this method, characterization of the amorphous form is
possible quickly. The starting material and five prepared
samples were tested at first by DSC. These curves are
presented in Fig. 1. The crystalline CLP melted at 177.4 C
(450.6 K). The normalized heat capacity change was
83.9 Jg-1. The sample which was treated with acetone
remained in the crystalline phase. The melting point of this
material was 177.8 C (450.9 K) and the normalized heat
capacity change was 82.6 Jg-1. The samples prepared in
ethanol or methanol were transformed to the amorphous
form both on drying through blowing with room temper-
ature air and with vacuum. The characteristic melting point
disappeared completely from the DSC curves which were
straight lines without any enthalpy changes; no Tg could be
detected.
Samples were also tested by XRPD measurement.
Diffractograms are can be seen in Fig. 2; for clarity, the
diffractograms are displaced along the y axis. This investi-
gation supported the DSC results throughout. Figure 2
shows that the products prepared with ethanol or methanol,
independently of the drying procedure were converted to the
amorphous form, because the peaks disappeared from the
diffractograms, and the spectra became smooth. The sample
treated with acetone remained in the crystalline phase, and
the diffractogram of this preparation was the same as that of
the crystalline starting material.
To confirm that no degradation occurred in the prepared
samples FT-IR analysis was performed (Fig. 3). For
clarity, these spectra too have been displaced along y axis.
Each peak was present in each spectrum, reflecting the
presence of the same chemical bonds and no degradation
could be detected in the course of these measurements. The
amorphous and crystalline materials furnished the same
spectra. Thus, as we had anticipated with this method we
could not differentiate the crystalline and the amorphous
forms, but we confirmed that no degradation happened in
samples.
The DSC, the XRPD, and the FT-IR results suggested
that the samples prepared with ethanol or methanol were
transformed to the amorphous form independently of the
drying procedure, but the sample treated with acetone
remained in the crystalline form. The acetone is not
suitable solvent for amorphizing CLP, but ethanol and
methanol have the same amorphizing property in the case
Fig. 1 CLP samples measured by DSC. (A) Crystalline form,
(B) sample prepared with ethanol, dried with blowing of room
temperature air, (C) sample prepared with ethanol, dried by vacuum,
(D) sample prepared with methanol, dried with blowing of room
temperature air, (E) sample prepared with methanol, dried by vacuum,













Fig. 2 CLP samples measured by XRPD. (A) Crystalline form,
(B) sample prepared with ethanol, dried with room temperature air,
(C) sample prepared with ethanol, dried by vacuum, (D) sample
prepared with methanol, dried with room temperature air, (E) sample
prepared with methanol, dried by vacuum, (F) sample treated with
acetone, dried by vacuum














Fig. 3 CLP samples measured by FT-IR. (A) Crystalline form (P II),
(B) sample prepared with ethanol, dried with room temperature air,
(C) sample prepared with ethanol, dried by vacuum, (D) sample
prepared with methanol, dried with room temperature air, (E) sample
prepared with methanol, dried by vacuum, (F) sample treated with
acetone, dried by vacuum
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of this API. If we apply a solvent in a pharmaceutical
technological method, we must take care of the danger
class of this solvent according to the ICH Q3C guideline
[27]. The objective of this guideline is to recommend
acceptable amounts for residual solvents in pharmaceuti-
cals for the safety of the patient. ICH Q3C classifies
ethanol into the less dangerous Class 3, while methanol is
classified into the more dangerous Class 2. According to
these facts, we suggest the application of ethanol for
amorphizing CLP.
Measurement of Tg
As mentioned in the Introduction, Tg is a very important
parameter for amorphous materials. The expected tem-
perature interval, in which Tg can lie, is approximately
2/3 to 4/5 of Tm (in Kelvin) [2]. The Tm of crystalline
CLP is 177.4 C (450.6 K). Accordingly, the expected
interval of glass transition is 27.2–87.3 C (300.4–
360.4 K), in this temperature interval we expected the
appearance of Tg.
A DSC curve reveals all structural changes accompanied
by enthalpy changes. In the curve, Tg is usually indicated
by a step, a dislocation from the baseline. For CLP, how-
ever, during the first heating run Tg could not be detected,
but during the second heating Tg appeared in the curve
(Fig. 4). When double heating was carried out with two
samples with ethanol, the endothermic step in the DSC
curve was detected in the same interval. This temperature
interval 82–110 C (355–383 K) can be defined as glass
transition of CLP. The midpoints of these changes were
89.4 C (362.6 K) and 88.5 C (361.6 K), with a mean of
88.9 C (362.1 K). Thus for the calculation this mean of
values (88.9 C = 362.1 K) was applied as Tg. For CLP,
therefore the quotient Tg/Tm is 0.80, and accordingly this
API can be classified as a good glass former.
Preliminary stability testing
In the case of amorphous materials, stability problems can
occur because of the higher energy level. The possibility of
recrystallization is very notable. The amorphous CLP was
subjected to preliminary stability testing. A sample pre-
pared with ethanol was stored in a closed glass container at
23 ± 2 C and 55 ± 5 relative humidity. It was observed
that crystal growth started after 30 days (Fig. 5). The
crystallinity of the sample increased for approximately
76 days and crystal growth then stopped. The characteristic
Tm appeared in curve B at 172 C (445.2 K). This peak
increased linearly with time, but the change stopped after
76 days. Tm was found in the interval of 170–172 C
(443.2–445.2 K). Values of DH are given in Table 1. It was
clear that recrystallization started in the amorphized
sample.
Fig. 4 Glass-transition temperature of CLP measured by DSC.
(A) Sample prepared with ethanol, dried with room temperature air,
(B) sample prepared with ethanol, dried by vacuum
Fig. 5 Preliminary stability testing: (A) fresh sample, (B) sample
stored for 30 days, (C) sample stored for 34 days, (D) sample stored
for 45 days, (E) sample stored for 76 days, (F) sample stored for
96 days, (G): sample stored for 109 days
Table 1 Preliminary stability testing: changes in DH determined by
DSC measurement
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Conclusions
In the course of this study, CLP was amorphized by the
solvent method. Both ethanol and methanol as solvent
resulted in amorphous samples. Either can be a suitable
solvent for amorphization, but ethanol is preferred in view of
the ICH guidelines relating to residual solvent. Methanol
belongs to Class 2, and ethanol in the less dangerous Class 3.
In the sample drying procedures, blown room temperature
air, and vacuum drying have the same effectiveness. Tg was
determined to be 88.9 C (362.1 K), the quotient Tg/Tm was
0.80, so CLP is a good glass former. The results of the
preliminary stability testing indicated that recrystallization
occurred in the pure amorphized API after 30 days at room
temperature. The application of crystallization inhibitors is
therefore suggested.
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